Five Years of Progress

When the Myelin Repair Foundation began funding research in 2004, we set an audacious goal: To license our first myelin repair therapeutic target for commercial development in five years. This was 15-20 years faster than most people thought to be possible. Achieving this short-term goal is the first of many milestones toward our greater goal of rapidly developing and delivering myelin repair treatments to Multiple sclerosis patients.

Addressing Every Phase of Drug Development

The Myelin Repair Foundation is the only research organization that addresses every phase in the drug discovery process, from initial research all the way to licensing by commercial drug developers. This is the only way to ensure that promising research results in real patient treatments – in the shortest amount of time.

Rollover each phase to learn about our progress to date.

Unlike many other research organizations, the Myelin Repair Foundation is committed to breaking down barriers to treatments across the entire spectrum of drug discovery from the basic biology to target validation, drug discovery, clinical trials and FDA approval.

By being engaged throughout the process, we are able to build a deeper understanding of how myelin is formed, damaged and repaired and carry that information forward through each step in the process. Even failures offer important insights into discoveries, making learning why some experiments fail as important as celebrating those that succeed.

The results are stunning. For those interested in more detailed information on the science behind our achievements, see our research plan and read our scientific publications.